The Stoller Biomarker Discovery Centre (SBDC) was set up to help researchers embed the process of identifying biomarkers that have the potential to be used to diagnose or inform treatment of diseases.
The SBDC is recognised internationally for its approaches to proteomic biomarker discovery, verification and validation. All research themes use the SBDC to define and develop proteome biomarkers using this platform.
The Centre is hard-wired into the national Farr Institute via HeRC@Farr to ensure rapid merger of clinical and ‘omics data (including companion genomics data).
- Extending the lupus extended autoimmune phenotype (LEAP) study cohort, utilising detailed imaging and biomarker profiling to identify subsets with a common immunopathogenesis (disease development)